Trial register facet
Ongoing trial records
44 records with the status ongoing.
Showing 0 records on this page
Records
44 documents · page 1 of 2
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| TRIUMPH-1 | Retatrutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Not rated |
| TRIUMPH-2 | Retatrutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Not rated |
| TRIUMPH-3 | Retatrutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Not rated |
| TRIUMPH-4 | Retatrutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Not rated |
| TRIUMPH-OSA | Retatrutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Not rated |
| REDEFINE-4 | CagriSema (cagrilintide with semaglutide) | Phase 3 | Ongoing | Randomised, double-blind, active-controlled | — | — | Not rated |
| SYNCHRONIZE-1 | Survodutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Not rated |
| SYNCHRONIZE-2 | Survodutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Not rated |
| SYNCHRONIZE-CVOT | Survodutide | Phase 3 | Ongoing | Event-driven cardiovascular outcome trial | — | — | Not rated |
| PETRE-PH2-OBESITY | Petrelintide | Phase 2 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Not rated |
| DREAMS-3 | Mazdutide | Phase 3 | Ongoing | Randomised, double-blind, active-controlled | — | — | Not rated |
| MARITIDE-PH3 | Maridebart cafraglutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Not rated |
| TRIUMPH-1-RENAL-IMPprogramme record | Retatrutide | Phase 1 | Ongoing | Phase 1 ascending dose | — | — | Very low |
| TRIUMPH-2-REGIONAL-CNprogramme record | Retatrutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Very low |
| TRIUMPH-3-OLEprogramme record | Retatrutide | Phase 3 | Ongoing | Single-arm open-label | — | — | Very low |
| TRIUMPH-4-BODY-COMPprogramme record | Retatrutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Very low |
| TRIUMPH-OSA-OLEprogramme record | Retatrutide | Phase 3 | Ongoing | Single-arm open-label | — | — | Very low |
| REDEFINE-4-RENAL-IMPprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 1 | Ongoing | Phase 1 ascending dose | — | — | Very low |
| SYNCHRONIZE-1-ELDERLYprogramme record | Survodutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Very low |
| SYNCHRONIZE-2-REGIONAL-JPprogramme record | Survodutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Very low |
| SYNCHRONIZE-CVOT-RENAL-IMPprogramme record | Survodutide | Phase 1 | Ongoing | Phase 1 ascending dose | — | — | Very low |
| MARITIDE-PH3-RENAL-IMPprogramme record | Maridebart cafraglutide | Phase 1 | Ongoing | Phase 1 ascending dose | — | — | Very low |
| DREAMS-3-BODY-COMPprogramme record | Mazdutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Very low |
| PETRE-PH2-OBESITY-REGIONAL-JPprogramme record | Petrelintide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Very low |
page 1 of 2